Merck announced on April 22, 2025, that Health Canada approved KEYTRUDA (pembrolizumab) in combination with pemetrexed and platinum chemotherapy. This approval is for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM).
The approval is based on data from the pivotal Phase 3 IND.227/KEYNOTE-483 trial, which demonstrated a statistically significant improvement in overall survival. This expands Keytruda's indications in Canada, providing a new treatment option for patients with this aggressive cancer.
This regulatory milestone reinforces Keytruda's broad utility across various cancer types and strengthens Merck's oncology portfolio in the Canadian market. It contributes to the continued growth of Merck's flagship product.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.